ARCE Cell Technology Platforms
ARCE Therapeutics, a Taiwan based biotech company, specializes in developing proprietary gene-modified cellular immunotherapies. ARCE’s CAR-T/NK cell therapy products are developed via three technologies, DashCAR®, MaxCAR®, and OneCAR®, for CAR immune cell therapy with high efficacy, safety, and durability, and thus to achieve a sustained improved response capable of conquering human diseases.
Main Product
- ARD103 (CLL-1 DashCAR®-T)
- Indication: blood cancer relapsed/refractory AML
- Target: Human C-type lectin-like molecule 1 (CLL-1)
- The median of expression rate of CLL-1 on tumor cells of all patients was 85.2%.
- CLL-1 is expressed on both blasts and leukemia stem cells, but not on hematopoietic stem
cells.
Product Features:
- Ultrafast DashCAR® bioprocess in 3 days
- High productivity with >80% CAR+
- Engineered cells conserving stemness>80%
- High specificity without off-target issues
- Safe with limited hematotoxicity
- Proved efficacy & durability in animal models
- IND-enabling targeted IND in Q4/2023
Business Interests
- CLL-1 CAR-T product early-entry to the market
- Seek partners to collaborate the U.S. and global clinical development
- Seek out-licensing opportunity
- Discovery Products/Platform Collaboration
- No CRO/CMO contacting
ARCE Therapeutics, a Taiwan based biotech company, specializes in developing proprietary gene-modified cellular immunotherapies. ARCE’s CAR-T/NK cell therapy products are developed via three technologies, DashCAR®, MaxCAR®, and OneCAR®, for CAR immune cell therapy with high efficacy, safety, and durability, and thus to achieve a sustained improved response capable of conquering human diseases.
Main Product
- ARD103 (CLL-1 DashCAR®-T)
- Indication: blood cancer relapsed/refractory AML
- Target: Human C-type lectin-like molecule 1 (CLL-1)
- The median of expression rate of CLL-1 on tumor cells of all patients was 85.2%.
- CLL-1 is expressed on both blasts and leukemia stem cells, but not on hematopoietic stem
cells.
Product Features:
- Ultrafast DashCAR® bioprocess in 3 days
- High productivity with >80% CAR+
- Engineered cells conserving stemness>80%
- High specificity without off-target issues
- Safe with limited hematotoxicity
- Proved efficacy & durability in animal models
- IND-enabling targeted IND in Q4/2023
Business Interests
- CLL-1 CAR-T product early-entry to the market
- Seek partners to collaborate the U.S. and global clinical development
- Seek out-licensing opportunity
- Discovery Products/Platform Collaboration
- No CRO/CMO contacting
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
